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Isolation and chemical identification of inhibitors of plasma ligand
binding. The binding by serum albumin of many drugs and endogenous
metabolites is impaired in humans and animals with renal failure.
Unknown solute(s) retained in renal failure have been extracted from
uremic fluids. When added to normal plasma they induce a similar
binding defect. Similar activity can be extracted from normal urine. We
have devised a series of extraction and purification techniques that
yielded three binding inhibitory ligands from normal human urine in
sufficient quantity and of a high degree of purity. Rigorous methods
have been applied to determine chemical identity of the ligands.
Purification steps consisted of: (a) adsorption at pH 3.0 to polysty-
rene—divinylbenzene resin (XAD-2); (b) elution from the resin with
methanol followed by drying and solution in dilute formic acid; (c)
passage through SP-Sephadex to remove cations, especially yel-
low—brown pigments; (d) adsorption to the anion exchanger QAE-
Sephadex, and separation into three zones of inhibitory activity with a
formic acid gradient; (e) purification to homogeneity with C-S or C-18
silica reversed—phase chromatography. Using this isolation procedure,
followed by mass spectroscopy and nuclear magnetic resonance spec-
troscopy, we have shown that the binding inhibitory activity is due
not to one ligand, but to a family of aromatic acids. To date hippurate,
f3-(rn-hydroxyphenyl)—hydracrylate and -hydroxyphenylacetate have
been identified as binding inhibitors. Other active ligands remain to be
identified.
Despite extensive efforts by many investigators, the chemical
basis of most uremic disorders remains unknown. The myriad
of functional disturbances which occur in advanced renal failure
are accompanied by increased retention of a vast number of
individual chemicals [1—3]. Specific cause and effect relation-
ships are extremely difficult to prove in such a tangle of multiple
variables. We have focused on a simple, limited uremic disorder
hoping to establish its specific chemical basis and to find general
strategies useful to the solution of more complex cause/effect
relationships in uremia.
The binding by serum proteins, in particular albumin, of
many drugs as well as endogenous metabolites (such as
tryptophan, bilirubin) is impaired in humans and animals with
renal failure, the degree of impairment being only roughly
proportional to the degree of azotemia [4—6]. Substantial evi-
dence has accumulated indicating that unknown solutes re-
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tamed in uremic body fluids bind to serum proteins and thereby
reduce the number of binding sites or the affinity for competing
ligands. Substantial or complete normalization of binding can
be achieved by separation and purification of albumin from
uremic plasma or by treatment of whole uremic plasma, espe-
cially at low pH, with activated charcoal or resins, or by organic
solvent extraction [5, 7—11]. Extracts of uremic fluids, prepared
by several different methods, when added to normal plasma
impaired binding of several ligands, such as chloramphenicol,
phenytoin, tryptophan [12, 13]. We have used methanol extrac-
tion of the non-ionic resin used to absorb acidified uremic fluids
as the source of the uremic binding inhibitor. Preliminary
studies suggested that the inhibitor is a relatively non-volatile
aromatic acid, probably a carboxylate. The uremic extract also
inhibits uptake and excretion of para-aminohippurate (PAH) by
rat kidneys [14, 15].
We have utilized a variety of separation methods in an effort
to obtain the binding inhibitor in pure form and to determine its
chemical structure. Because of the need for large quantities of
materials for development of isolation techniques, we mainly
utilized normal human urine, which we had shown is rich in
binding inhibitors [16]. Our initial assumption that we were
dealing with a single chemical is clearly incorrect. These studies
identify several inhibitors isolated from normal urine and de-
scribe the merits and limitations of our sequential separation
methods.
Methods
Isolation of binding inhibitors
Six overnight collections of normal urine were obtained
without preservatives and free of medications or vitamin sup-
plements. Each collection was frozen and stored at —40°C until
pooled and processed. After thawing at 4°C and centrifugation
at 4,000 xg, the urine pool of 1,880 ml was acidified to pH 3.0
with 3 N HCI and subjected to adsorption to non-ionic resin.
Absorption to non-ionic resin. Several preliminary studies
were done with small aliquots of the normal urine pool (or
urernic pleural fluid) to determine optimum conditions for
adsorption of the inhibitors to XAD-2 type divinylben-
zene—polystyrene resin (Biobeads SM-2, 20 to 50 mesh, Bio-
Rad Laboratories, Richmond, California, USA) previously
shown to effect substantial correction of the abnormality in
binding of uremic plasma [12]. Pilot studies showed that resin
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Table 1.
XAD-2 resin
ml
Binding inhibition
%
0.2
0.6
1.0
—13.2
21.8
—22.2
Two ml of normal urine were titrated to pH 3.0 with 3 N HC1, mixed
with resin, agitated for 60 mm, washed three times with 5 ml of water
per wash (discarded) and inhibitors eluted with two washes of 5 ml
methanol each. The dried methanol residue was dissolved with 3 ml of a
normal plasma pool diluted 1:8 with water. To 2.25 ml of the diluted
plasma '4C-and unlabelled phenytoin were added and binding deter-
mined as described under Methods. A control sample (without resin
extract), run in parallel, showed 61.6% phenytoin binding.
adsorption in the pH range from 1.0 to 6.0 showed a sharp
increase in yield from —3.3% to —25.5% phenytoin binding
inhibition as pH was lowered. We chose pH 3.0 for adsorption
because we were concerned that the increase in yield at pH 1 .0
may have resulted from acid hydrolysis of labile, inactive
conjugates (such as glucuronides). We also determined the
optimum ratio of urine:resin volumes for adsorption (Table 1).
A column technique was unsatisfactory for adsorption and
elution because air pockets developed with channeling of flow
during changes in fluid composition of urine to water and water
to methanol. Adsorption was conveniently accomplished in
bulk fashion. The urine:resin mixture was gently stirred me-
chanically in a beaker for two hours, then poured into a large
sintered glass funnel. After aspiration of the urine, the resin was
washed three times with 200 ml portions of distilled water.
Urine and water washes were discarded.
Elution from resin. Solvents tested as eluants included
ethanol, methanol, methanol: ethylene dichloride, acetone and
ethyl acetate. Yield of binding inhibitory activity from the resin
after methanol washes was equal to or only slightly less than
with the other solvents. Because of its low boiling point, safety,
and ready availability in very pure form, we chose to use
methanol for preparative scale work.
The resin was extracted repeatedly with 200 ml of methanol,
each extraction being for one hour with periodic stirring of the
resin. Over 96% of the total inhibitory activity was in the first
five washes, which were pooled and dried in small aliquots at
room temperature under vacuum. The oily residue was ex-
tracted four times with a total of 150 ml of 50 mM formic acid
(HCOOH). The formic acid extraction yielded greater than 96%
of the original inhibitory material, while excluding inactive
lipids present in the methanol extract.
The large amount of costly resin could be reused without loss
of activity by applying the following clean—up procedure, The
used resin was first boiled for 5 minutes in 0.1 M NaOH to digest
adsorbed proteins—especially important after extraction of
plasma. After rinsing repeatedly with three volumes of distilled
water, the resin was transferred into the sintered glass fun-
nel/flask apparatus described above. After removal of water
with vacuum, four washes with acetone of one bed volume each
(10 minutes each wash) were followed in the same manner with
chloroform and methanol washes. All traces of methanol were
removed with copious water washes (—100 bed volumes). The
recycled resin was stored in water at 4°C under a layer of
toluene added to inhibit bacterial growth.
Fig. I. Preparative scale chromatography on 1.0 X 24cm C-8 silica gel
column of urine extract, which had first been sequentially purified by
adsorption and elution from Biobeads, SP-Sephadex and QAE-Seph-
adex. Zone I residue from the last step was dissolved in and eluted with
10% acetonitrile/0.8% acetic acid in water. Absorbance was measured
at 260 nm. Phenytoin binding inhibitory activity was mainly found in
pool C (peak Ia) and pool D (peak Ib).
SP-sephadex purification. SP-Sephadex (Pharmacia Fine
Chemicals Inc., Piscataway, New Jersey, USA) was pre-
washed in bulk with water to remove fines, with 200 m formic
acid by frequent changes over six to seven hours, and equili-
brated with the 50 m formic acid until the pH was 1.39 in the
resin bed and 2.73 in the supernatant. The formic acid extract of
urine was passed through a small SP-Sephadex column. This
step eliminated considerable amounts of inactive, yellow—
brown pigment by adsorption to the gel, while most of the
inhibitory activity passed through the column.
Small scale pilot studies were performed to determine the
maximum load per volume of gel which could be applied
without loss of activity. In the final preparative work a 1.5 x 14
cm SP-Sephadex column was used for purification of half of the
methanol extract (containing 96,000 inhibitory units as defined
below). The formic acid extract was applied at a rate of 54 mI/hr
and washed at the same rate with 50 m formic acid. The first
5 ml were discarded. The subsequent 100 ml were collected,
assayed for activity, and dried by rotary evaporation under
vacuum at room temperature. The extract was redissolved in
distilled water and titrated from pH 2.5 to 5.7 with 3 N NaOH.
Anion—exchange chromatography. After extensive prelimi-
nary studies, we found that DEAE-Sephadex or QAE-Seph-
adex in formate form with a formic acid gradient produced a
smooth, descending pH gradient (see Fig. 2 of 116]). We
preferred QAE-Sephadex because it had cationic groups with
lower pK values. QAE-Sephadex (chloride form) was first
converted to formate form by prolonged washing, in column
form, with 2 liters of 1.0 M sodium formate over two days. This
method produced much faster exchange than use of 1.0 M
formic acid. Low ionic strength and pH equilibration were then
achieved using two liters of 15 mM HCOOH (over three days)
followed by two liters of 1.0 ms's HCOOH (over two days). The
final pH values were 5.8 in the supernatant and 3.4 in the resin
bed. We initially generated a linear formic acid gradient for low
pressure chromatography. Elution of a model standard (hip-
E
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puric acid) showed some tailing. To correct this problem a
linear pH gradient was achieved by construction of a two
chamber device connected in series with a peristaltic pump
(Gilson Medical Electronics Inc., Middleton, Wisconsin, USA).
The reservoir consisted of a 3.3 X 21 cm glass cylinder
connected via a short horizontal glass tube at one side near its
bottom to a mixing chamber with similar glass connecting
tubes. A stopcock was inserted between the reservoir and the
mixing chamber. The mixing chamber was constructed from a
250 ml conical glass Erlenmeyer flask, the top of which was
sealed with a flat glass surface and the bottom of which was cut
off at the point where the straight sides joined the curved
bottom. This flask was inverted so that the bottom was 2.1 cm
and the top 7.3 cm in diameter, with a height of 11 cm. An exit
side tube off the bottom of the mixer connected via a stopcock
and teflon tubing to the pump.' The sequence of formic acid
concentrations used with a 1.5 x 27 cm gel bed were:
(1) 1 mM HCOOH at 34 mI/hr followed by 5 mi HCOOH at
17 ml/hr to wash through inactive ligands (22 hours)
(2) 76 ml of 325 msi HCOOH into 174 ml of 5 mrvt HCOOH at
60 mI/hr
(3) 76 ml of 5,000 m HCOOH into 174 ml of 325 mM
HCOOH at 60 mI/hr
(4) 5,000 mrs'i HCOOH directly into the column at 30 to 60
mi/hr until absorbance was close to background.
For further resolution of QAE-Sephadex peak I, we first used
a repeat QAE-Sephadex column with isocratic 50 m formic
acid as eluant. A very broad, complex peak was found for
binding inhibition. The most active fractions were pooled,
dried, and dissolved in 10% acetonitrile/0.8% acetic acid. This
pool was further purified with the Lobar' C-8 column as
described below for peak 11.
Crystallization. The central fractions in peak II from the
QAE-Sephadex column (see Fig. 2 of [16]) spontaneously
crystllized at room temperature. The bulk of peak TI, including
the crystals, was pooled, flash evaporated, and the residue was
redissolved with 10 ml of methanol to yield a yellow solution.
The solution was dried in a stream of nitrogen. The residue was
dissolved with 4 ml of hot distilled water while shaking in an
83°C water bath. Crystallization occurred on cooling to room
temperature. After overnight refrigeration, the yellow superna-
tant was decanted and the crystals were washed four times with
2.0 ml fractions of cold H20. After two more identical crystal-
lizations, 137 mg of clear, colorless crystals were obtained.
Reversed—phase liquid chromatography. For large scale pre-
parative chromatography we used a 1 .0 x 24 cm C-8 silica gel
column (Lobar', Merck, Inc., Darmstadt, Germany), which
contained 40 to 63 rm irregular particles. For analytical
reversed—phase high performance chromatography (RP-HPLC)
and for small scale preparative work we used a 0.46 X 25 cm
C-18 silica column with 5 m particles (UltrasphereR ODS,
Beckman Instruments, Inc., Fullerton, California, USA).
Crystallized material from peak 11 was dissolved in 10 ml of
12% acetonitrile/0.8% acetic acid, and six aliquots of 1.5 ml
each were injected into the Lobar column. This column had
been equilibrated with and was subsequently eluted with the
same solvent mixture at 1.0 mi/mm. Greater than 95% of the
A diagram of this device is available from the authors on request.
material absorbing at 260 nm eluted in a single homogenous
peak at 49 mm, clearly separated from one small leading and
one small trailing peak, The main peak from each of the
injections was pooled, dried under a stream of nitrogen gas, and
used for nuclear magnetic resonance (NMR) and mass spectros-
copy. The chromatographic system consisted of a model I bA
pump (Beckman), model 7125 injector (Rheodyne Inc., Cotati,
California, USA), HM Holochrome detector (Gilson Medical
Electronics, Inc., Middleton, Wisconsin, USA) and Model 291
recorder (Linear Instruments Corp., Irvine, California, USA).
Peak 1 was purified on the Lobar column by the same method
used for peak II except that the acetonitrile was 10% in the
mobile phase. Of seven peaks eluting in the isocratic phase, the
fourth and fifth (designated Ia and Ib) eluting at about 37 and 57
minutes had the highest UV absorbance and gave the strongest
binding inhibition. Peak Ia was further purified with the Lobar
column using 8% methanol/l.0 msi Rd. The main component
in Ia was well separated in 96 minutes from three other small
peaks, and the main component was pure when tested by
analytical C-l8 HPLC and paper chromatography. However,
after the pool of five injections was dried, impurities appeared
as a result of methylation during the drying step, as indicated by
the appearance in the 'HNMR spectrum of this material of two
singlets, one of which at 3.7 ppm was very intense. This mixture
was, therefore, repurifled with the C-18 Beckman Ultrasphere
ODS column using a 45 minute gradient from 5 to 12%
acetonitrile/0,8% acetic acid followed by isocratic 12%
acetonitrile/0.8% acetic acid elution. This program resulted in
resolution of the main component of Ia from impurities. The
purified Ia remained homogenous after drying.
The second active component from the first preparative C-8
Lobar column, designated Ib, was further purified with a C-8
Lobar column using 10% methanol/l mrvt HCI as eluant. A
single peak eluted with a very small contaminant detectable at
220 nm. This small impurity was removed by passage through a
1.0 x 25cm C-18 Beckman ODS column (10 rm particles) using
8% methanol/7 m acetic acid (pH 3.5).
NMR and mass spectroscopy. Preliminary studies were made
to obtain clues to the structure of the principal component in
substantially purified preparations. The dry solids were dis-
solved in appropriate solvents and in some cases derivatives
were prepared as described for individual preparations under
results. Proton and carbon nuclear magnetic resonance ('H- and
'3C-NMR) spectra were obtained at 200 MHz and 360 MHz with
Nicolet NT-200 and NT-360 spectrometers at the University of
California, Davis NMR Facility. Electron—impact high resolu-
tion mass spectra (EIHRMS) were obtained with a modified
AEIMS-50 spectrometer at the Biomedical and Environmental
Mass Spectrometry Resource, Space Sciences Laboratory,
University of California, Berkeley, or with a 70 cv Dupont 492
Spectrometer with a Finnigan—lnco Data System at the Univer-
sity of California, Davis. Similar methods were used to analyze
totally pure samples, except as noted in the text, individual
figures, and tables. Conventions for presentation of NMR and
EIHRMS results are given in the journal Phytochemistry.
Miscellaneous methods and materials. Several methods were
used to verify purity and to compare chemical properties of
isolated inhibitors with pure standards. Mixtures of isolated
inhibitors and pure samples of the postulated chemical were
co-chromatographed by analytical HPLC using a variety of
394 Gulyassy et a!
solvent systems and detection wavelengths. The compound Ta
was chromatographed on Whatman #1 paper with two solvent
systems, isopropyl alcohol:ammonia:water (8:1:1) and ben-
zene:propionic acid:water (2:2:1). Papers were sprayed with
one of two detection mixtures, diazotized sulfanilic acid or
diazotized p-nitroaniline, to compare R1 and specific color
reactions with known standards 11171. Ultraviolet spectra were
obtained using a Beckman DU-7 Single Beam Spectrophotom-
eter or a Beckman Model 24 Spectrophotometer. Melting points
were determined in open capillary tubes on a Mel-Temp appa-
ratus (Thomas Scientific, Philadelphia, PA) and are uncor-
rected. Optical rotations were determined with a Carl Zeiss
0.005 Photoelectric Polarimeter (Zeiss, Oberkochen, FRG)
Aromatic acids were purchased from Sigma Chemical Co.
(St. Louis, Missouri, USA). HPLC grade acetonitrile was from
EM Industries Tnc. (Gibbstown, New Jersey). Other chemicals
and solvents were of reagent grade.
Determination of plasma binding and inhibition of binding
Binding inhibitory activity of urine extracts, column fractions
and pools was determined by centrifugal ultrafiltration in cello-
phane tubing at 37°C as previously described [111 with minor
modifications. Pools of normal test plasma were diluted 1:8
with distilled water. The dried residue from column fractions or
pools of fractions was dissolved with 3.0 ml of the diluted
normal plasma. This mixture was left overnight at 4°C. To 2.25
ml of the mixture, '4C-phenytoin (50 l) and unlabelled
phenytoin (75 d) were added for a final total phenytoin con-
centration of 16 g/ml. Percent binding was then determined by
centrifugal ultrafiltration. For some highly acidic samples it was
necessary to neutralize the extracts or pools before addition to
the test plasma, otherwise turbidity and false positive inhibition
resulted. Very dilute samples were first evaporated and dis-
solved in a smaller volume of water or directly in the test
plasma to increase the accuracy of the assay. Aliquots were
chosen to yield above 5% and below 25% inhibition, the region
of linear dose—response [12]. An inhibitory unit (Inh.U.) is
defined as a decrease of 1.0% '4C-phenytoin binding in the test
mixture compared to the control sample under the assay
conditions described.
Extraction with XAD-2 of arc,matic acids from aqueous
buffered solutions
Because overall recovery was obviously dependent on the
initial adsorption to the XAD-2 resin and subsequent water
washes, recovery in these critical steps was evaluated using
model aromatic acids dissolved in aqueous buffer. In a scaled
down model of the preparative XAD-2 resin adsorption proce-
dure, 0.15 ml of 2 m p-OH benzoate, p-OH phenylacetate,
indole-3-acetate or 3-phenyipropionate or 0.15 ml of 6 mM
indoxyl sulfate was mixed with 2.85 ml of buffer and 0.6 ml of
resin. The buffer consisted of 115 msi NaCl/25 m sodium
acetate titrated to pH 3.0 or 7.0 with glacial acetic acid. The
indole-3-acetic and 3-phenylproprionic acids were made soluble
in the stock solutions by addition of 3 N NaOH. For studies
with hippurate, the solid was dissolved directly in the buffer to
yield a final concentration of 2.0 m. Three ml of the 2.0 mM
hippurate was added to 0.6 ml of resin. The mixtures were
rocked for two hours at room temperature. After the superna-
tants had been separated, the resin was washed three times with
3.0 ml of water per wash and the washes were pooled. Three
subsequent washes with 1.2 ml each of methanol were pooled.
The three final washes were with 1.2 ml of ethylene dichioride.
The pooled washes were used as such or flash evaporated,
redissolved in more concentrated aqueous solutions and, ex-
cept for indoxyl sulfate, recoveries were quantitated by analyt-
ical HPLC using 0.8% acetic acid and acetonitrile concentra-
tions in gradient or isocratic mode as best for each ligand.
Indoxyl sulfate was quantitated by analytical HPLC using an
ion—pairing method [18].
Results
At the time these studies were begun we had no precise
information about the chemical nature of the binding inhibitor.
Tt was, therefore, not possible to define recovery in the first
steps, which consisted of adsorption at pH 3.0 to the XAD-2
resin and elution with methanol, The pool of six overnight urine
collections contained 4.48 g of creatinine and a total of 66.75 g
of dry solids. Of the total yield of 207,000 inhibitory units
(Inh.U.) in the seven methanol washes of 200 ml each, over 96%
was in the first five washes. If extraction was complete the
original urine specific activity would be 3.1 Inh.U./mg. The next
steps were to dry the 1,000 ml methanol pooi and dissolve it in
50mM HCOOH. Recovery of lnh.U. for these steps was 96.5%,
The XAD-2 resin adsorption and SP-Sephadex column steps
removed 95.3% of original dry solids. The recovery of Inh.U.
from the SP-Sephadex column was 81%. A more substantial
lnh.U. loss of 26% occurred during the subsequent steps,
drying of the eluate, solvation with water and titration to pH
5.8.
The XAD-2 eluate was purified with sequential SP-and QAE-
Sephadex columns. Recovery of Inh.U. from all tubes and
pools from the QAE-Sephadex column equaled 96.5%. The
three peaks of inhibitory activity, designated I, 11, and III,
eluted in the pH ranges 2.37 to 2.21, 2.13 to 1.94, and 1.88 to
1.70 (see Fig. 2 of [161). The major portion of peak II, consti-
tuting 42% of the eluted mb. U. from the first QAE-Sephadex
column, was used for further purification. The pool from the
second QAE-Sephadex column was dried, dissolved with meth-
anol and further purified by crystallization three times. The sum
of the three supernatants plus crystals yielded 12,700 Inh.U. for
an overall recovery of 79% for these steps.
An aliquot of peak 11(29 mg) was purified by C-8 silica
reversed phase chromatography. Recovery from this column
was quantitative. The material had a specific activity of 46.1
Inh.U./mg and was homogeneous on all checks of purity. These
tests consisted of analytical reversed phase HPLC with the 10
LM C-l8 silica column. A single, symmetrical peak was ob-
tained using peak TI material and elution with (a) 12%
acetonitrile/0.8% acetic acid with detection at 260 nm, (b) 12%
methanol/1.0 m HCI detection at both 220 and 260 nm; (c)
elution of a mixture of peak TI material and known hippuric acid
with system "a"; and (d) overloading with peak 11 material (4x
off scale) and elution with an acetonitrile gradient from 5% to
80% in 0.8% acetic acid and detection at 260 nm.
The UV spectrum, 'H NMR spectrum [19] and EIHRMS (mlz
179.0560; calc. for C9H9NO 179.0582) of peak II material
were indistinguishable from those of hippuric acid. Melting
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Fig. 2. 360-MHZ 'HNTVIR spectrum of (S-(—)-m-HPHA in D20. The
inset shows the CH, resonances on irradiation aT5.07 ppm.
point (mp) was 188 to 1900, literature mp 188 to 191° [201,
mixture mp with hippuric acid, 188 to 190°.
The major portion of peak I consisting of 19% of the total
Inh.U. off the QAE-Sephadex column was further purified. The
dried pool had a specific activity of 41.5 Inh.U./mg. The first
C-8 silica reversed—phase HPLC separation with isocratic 10%
acetonitrile/0.8% acetic acid as eluant yielded seven major UV
absorbing peaks, the fourth and fifth being the largest in terms
of both UV absorption and inhibitory activity (Fig. 1). These
peaks were designated Ia and lb respectively.
Pools of the Ia fractions (28 Inh.U./mg) were further purified
using the C-8 silica reversed—phase column and methanol as
organic solvent with a subsequent specific activity of 21
Inh.U./mg. Though impure, the 'H- arid '3C-NMR spectra
indicated that the major component was -(rn-hydroxyphenyl)-
hydracrylic acid (rn-HPHA).
Repurification with acetonitrile/0.8% acetic acid, yielded the
main component (Fig. 2) which was weakly levorotatory at 578
nm and had a UV spectrum (8% methanol/i m HC1) identical
to that of m-HPHA; 'H NMR (360 MHz, D20): o2.77 (d,d,J =
6.2, 15.7 Hz, C2-HA), 2.82 (d,d,J = 7.2, 15.7 Hz, C,-HA'), 5.08
(app. t,J 6.8 Hz, C3-H), 6.84 (d,d,J = 1.4, 8.0 Hz, C4-H), 6.91
(d,J = 1.4 Hz, C2-H), 6.97 (d,J 8.0 Hz, C6-H), and 7.30 ppm(app,t,J = 8.0 Hz, C5,H);T3C NMR (50.3 MHz, D20): b43.l
(C2), 70.2 (C3), 112.9 (C,), 115.1 (C4), 118.0 (C6), 144.4 (C,),
155.8 (C3) and 175.0 (C,) ppm; ms, m/z (rd. intensity) 182.0576
(C9Hj(,O4, 59.5), 164.0478 (C9H8O3, 5.8), 136.0518 (C5H8O2,
6.5), 123.0441 (C7H702' , 80.2), (122.0358 (C7H6O2, 48.7),
95.0498 (C6H7O, 100.0), 91.0544 (C7H7 , 13.4), and 65.0400
(C5H3, 28.1).
The pooi of peak Tb fractions from the first C-8 silica
preparatory column was dried (assayed at 10.7 Inh.U./mg),
dissolved in mobile phase (10% methanol/l.0 mH HC1) and
purified with the same column with isocratic elution. Specific
activity after this second C-8 column increased to 21 Inh.U./mg.
A third purification with the preparative RP C-l8 column
removed a small impurity.
The 'H NMR spectra [191 and EIHRMS (m/z 152.0462; calc.
for C5H8O 152.0473) of lb were indistinguishable from those
Table 2.
Stage and sample A B C D E F
(1) Resin supernatant 36.5 39.4 38.1 29.4 1.6 0.0
—
(2) Water wash 5.7 37.4 17.3 15.0 0.0
—
0.0
—
(3) Methanol extract 11.9 20.0 40.7 46.5 67.8 52.6
(4) CH,C], extract 1.2 2.4 6.3 7.4 14.9 15.3
(5) Sum 55.3 99.2 102.4 98.3 84.3 67.9
Percent recovery of model aromatic amino acids from pH 3.0 buffer.
After the acids were adsorbed to XAD-2 resin, the supernatant was
removed (stage 1). The resin was washed with water (stage 2) and
subsequently extracted in sequence with methanol and ethylene chlo-
ride (stage 3 and 4). Values are means sri of three to six replicates.
Abbreviations are: A, indoxyl sulfate; B, p-hydroxybenzoate; C, p-
hydroxyphenylacetate; D, hippurate; E, indole-3-acetate; F, 3-phenyl-
propionate.
of p-hydroxyphenylacetic acid. The fully purified peak lb
material was chromatographed with known pure p-hydroxy-
phenylacetic acid on a RP C-18 silica analytical HPLC column.
A single symmetrical peak was eluted with 12% acetoni-
trile/0.8% acetic acid and with 30% methanol/l .0 mrvi HCI.
The isocratic system eluted less than 26% of the inhibitory
activity from peak I loaded on the first C-8 preparatory column
(Fig. 1). After the isocratic elution of peaks Ia and lb. the
column was flushed with 100% acetonitrile. This eluate was
collected, dried, and run on the analytical RP C-18 silica column
using 0.8% acetic acid and a series of acetonitrile gradients from
10% to 99.2% of the organic solvent, The eluant, containing 10
major and at least 30 minor U-V absorbing peaks, was collected
in seven pools. The inhibitory activity was almost equally
divided among the second through sixth pools.
As shown in Table 2 the polar compounds, p-hydroxybenzoic
and p-hydroxyphenylacetic acids, adsorb poorly to the resin
and re substantially lost in the supernatant and subsequent
water washes. The intermediate polarity acid, indole-3-acetic,
is totally extracted by the resin and none is lost in the water
washes. The methanol extract removes a substantial fraction of
the adsorbed organic acid but more complete removal requires
a highly hydrophobic solvent. 1-lippurate showed an intermedi-
ate pattern of recovery. The most hydrophobic compound,
3-phenylpropionate, showed a pattern similar to that of indole-
3-acetic acid but a significant fraction remained bound to the
resin even after the ethylene chloride washes. Indoxyl sulfate
also was incompletely recovered.
Discussion
The inhibitors of protein binding that are present in body
fluids of patients with advanced renal failure presumably accu-
mulate because they fail to he excreted. Although other expla-
nations for their accumulation can be postulated we sought to
investigate this simple "failure of excretion" theory by exam-
ining normal human urine for inhibitors of protein binding.
Since normal urine contains binding inhibitory activity [161 and
is more plentiful than uremic serum, it was possible to apply a
liberal trial and error approach in refining the extraction and
purification techniques, which were then applied to less readily
available serum samples.
3.0 2.8
7.4 7.2 7.0 6.8 5.2 5.0 4.8 2.8 2.6
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Our earlier studies provided some general information about
the chemical nature of the uremic binding inhibitors. Extraction
of inhibitory activity from acidified uremic plasma by poly-
styrene—divinylbenzene resin indicated presence of a significant
hydrophobic component of these ligands. A shift from total
partition into water above pH 5 to substantial solubility in the
organic phase below pH 4 suggested the presence of an acidic
function, probably a carboxyl group [12]. Further studies using
ion—exchange Sephadex columns produced only rough separa-
tion but clearly showed that inhibitory activity was due to at
least three ligands [16]. The studies reported here show that the
number of binding inhibitory ligands may be even larger in
number. Three of these ligands, all aromatic carhoxylic acids,
have been isolated in pure form from normal human urine and
their chemical structures identified.
We first undertook purification of peak H, the second zone of
inhibitory activity from the QAE-Sephadex column, because it
was the largest peak and crystals spontaneously formed in the
acidic column effluent. Controlled crystallization allowed sub-
stantial purification of the bulk of the inhibitory activity in this
portion of the column effluent. Most but not all of the activity in
peak II was found in one subfraction obtained by re-
versed—phase preparatory HPLC. This suhfraction was purified
to homogeneity and determined by NMR, mass and UV spec-
troscopy, and melting point to be hippuric acid. The specific
activity of the hippuric acid was 46 Inh.U./mg compared to a
hypothetical initial value in the urine of 3 Tnh.U./mg. At the
specific activity of 46 lnh.U./mg the methanol extract content of
207,000 Inh.U. if entirely due to hippuric acid would require the
presence of 4,500 mg of this acid. The excretion of hippurate in
normals averages 253 mg/I [22]. The original 1.9 liter urine pool
contained 4.48 g of creatinine. Therefore, the bulk of the
inhibitory activity in the primary, methanol extract must have
been due to other ligands.
The second compound which we isolated and identified from
peak I, designated Ia, was shown to be (S)-(—)-(rn-
hydroxyphenyl)-hydracrylic acid (rn-HPHA) [201. The yield of
this obscure aromatic acid was considerably less than that of
hippuric acid. The specific activity of this material in nearly
pure form was 21 Inh.U./mg, about half that of hippuric acid. It
is curious that the specific activity of the nearly pure rn-HPHA
was less than that of the cruder pooi of peak I from the
QAE-Sephadex column, which assayed at 42 Inh.U./mg. One
possibility was that the crude pool contained a more potent
ligand, which was later separated from the rn-HPHA. Another
explanation would be partial race mization of (S)-(—)-rn-HPHA
during the isolation procedure. Binding to albumin is known to
be highly specific for certain chiral ligands, such as L-
tryptophan but not D-tryptophan is strongly bound 1231.
The complete NMR spectrum of rn-HPHA (Results, Fig. 2)
has not been previously reported to our knowledge. limited
data by Baba et al were in general agreement [241. We noted
susceptibility of rn-HPHA to methylation when a methanolic
solution was dried. In future work, especially when exact
quantitation of plasma or urinary levels is the goal, other
solvents should be used during extraction and isolation steps.
The third compound identified, p-hydroxyphenylacetate, had
a specific activity of 21 Inh.U./mg and was also a weaker
inhibitor than hippurate. Studies in our laboratory by
Tavares—Almeida of a large number of aromatic acids have
shown that addition of a hydroxyl, but not a methyl group, in
the para-position of phenyl acids sharply reduces ability to
inhibit plasma binding of salicylate, tryptophan and warfarin
[251.
Less polar ligands than p-hydroxyphenylacetate were eluted
from the reversed—phase silica column with a high concentra-
tion of acetonitrile. There was considerable inhibitory activity
in this eltiate, but partial separation of active components with
an acetonitrile gradient showed distribution of activity in five
fractions. The quantities in individual fractions were not suffi-
cient for isolation and identification studies.
The present isolation method has several advantages over
those generally used by investigators of uremic toxins. As
starting material most workers have used an ultrafiltrate of
uremic plasma, hemodialysate or the protein—poor late fractions
of gel chrornatographically resolved uremic plasma. All these
methods will yield low recovery of ligands bound to plasma
proteins. Acidification to pH 3 produces unfolding of albumin,
the principal plasma binding protein, with total or substantial
displacement of bound ligands into the "free" form. The low
pH also suppresses ionization of all but the strongest acids
enhancing their adsorption by the hydrophobic resin. After
adsorption to the XAD-2 resin, water washing removed essen-
tially all of the bulk solutes (urea, creatinine, sodium chloride,
etc.). Presence of these solutes could seriously interfere with
subsequent assays of uremic toxicity, such as protein binding,
lymphocyte stimulation, platelet aggregation.
This method could also be used to isolate and characterize
other classes of chemicals. Unionized hydrophobic compounds
should adsorb to the XAD-2 resin and elute in the methanol
wash. After drying they could be separated from acids or bases
by partition at the appropriate pH between immiscible aqueous
and organic phases. Bases would be adsorbed by the SP-
Sephadex column and could be eluted with an alkaline buffer.
Another feature of this study worthy of comment is the
rigorous proof of the chemical identity of the purified com-
pounds. In many reports on isolation of solutes from uremie
fluids, identification has been claimed when the unknown
co-chromatographs with a pure reference compound in several
or at times a single chromatographic system. Such evidence
cannot be taken as more than suggestive. 'FI-NMR, '3C-NMR,
mass and UV spectroscopy, and melting point determinations
have been used in this work to ensure the highest degree of
certainty in chemical identification.
The most abundant urinary inhibitor found in these studies,
hippuric acid, has long been known as a normal urinary
constituent of man and many animals, Its formation in liver
from benzoate and glycine requires coenzyme A and ATP.
Benzoate derives from both endogenous metabolism and inges-
tion of foods rich in benzoate, such as fruits and berries, or
those supplemented with benzoic acid as a preservative [26].
An important source of hippuric acid among hemodialyzed
patients is the heparin used, which contains benzyl alcohol as a
preservative.
Formation of hippuric acid was the first detoxification mech-
anism to be recognized. In normal man, ingestion of large
amounts of hippuric acid in treatment of urinary infections, or
of benzoate as a liver test, has been tolerated without significant
side effects 127, 28]. Mitch and Brusilow [29] fed 2.5 g of sodium
benzoate four times daily for five days to patients with moder-
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ately advanced azotemia. Serum hippurate rose from a mean
control value of 0.08 to the range of 0.76 to 5.43 mmol/liter the
morning after the five days of benzoate intake. No mention of
untoward effects was made in this study. It is unlikely that
hippurate is a major uremic toxin under most circumstances.
However, it is conceivable that hippurate, when present at a
high concentration in serum of patients with far—advanced renal
failure, could produce toxicity by interaction with plasma
albumin. Binding to serum albumin is a detoxifying mechanism,
reducing the free concent.ation of many potentially toxic drugs
and metabolites. By displacing any such highly toxic metabo-
lites from serum albumin, hippurate could indirectly cause
toxicity. The worsening of kernicterus by sulfonamide displace-
ment of biliruhin is an example of such an effect [30].
Additional effects of hippurate and other aromatic acids
have been shown on proximal tubular function. Studies in
Grantham's laboratory have shown that serum from uremic
patients caused net fluid secretion into isolated proximal
straight tubules from rabbit kidneys. Hippurate was estimated
to cause about one—fourth of the secretory activity, however
the method for measuring hippurate was not proven to be valid
for uremic serum 31]. Bourke et al showed that serum from rats
made acutely uremic inhibited uptake of paraaminohippurate
(PAH) and orthoiodohippurate by rat kidney slices and sepa-
rated rabbit renal tubules prepared from normal animals. Serum
hippurate in these rats, measured by a non-specific method, was
elevated to five times normal levels. Hippurate in the incubation
medium inhibited the uptake of PAH by normal rabbit tubules
but the concentration required for inhibition was much higher
than that found in the serum of the uremic rats [32].
Boumendil—Podevin et al found that serum and urine from
chronially uremic patients inhibited uptake of urate and PAH by
isolated renal cortical tubules of rabbits. Fractionation of the
serum and urine by gel filtration revealed several fractions, two
of which corresponded to the elution positions of hippurate and
indoxyl sulfate. Measurements of hippu rate and indoxyl sulfate
in serum of patients with severe chronic uremia by non-specific
methods showed markedly elevated levels (means SEM of 280
51 M, 220 78 ILM), which could in part account for the
inhibition of uptake [33].
The second compound identified, S-(—)-(rn-hydroxyphenyl)-
hydracrylic acid (rn-HPHA) is a much more obscure aromatic
acid. It was first isolated from normal urine by Armstrong and
Shaw during their extensive studies of urinary aromatic acids
[17]. Because the concentration varied widely among normals
and fell to very low levels in subjects ingesting an elemental
diet, they assumed that it was dietary in origin or derived from
metabolism of a dietary precursor. Urinary excretion of rn-
HPHA has been confirmed by several authors using more
modern analytical methods [24, 34]. The origin of rn-HPHA
appears to be the flavonoids, which are widely distributed in
plant foods. Das showed that rn-HPHA was the major urinary
metabolite of (+)-catechin fed to monkeys [351. Another source
is coffee. Shaw and Trevarthen showed a delayed increase in
urinary rn-HPHA seven to 15 hours after ingestion of 1,000 ml
of coffee by a normal subject [36]. We are unaware of any
studies of the potential toxicity of rn-HPHA in man or animals.
Its plasma concentration in uremic humans was found by Bajaj
et alto be 76 46 (mean SD) rg/dl using a paper chromato-
graphic method of unproven specificity [37].
Both systemic metabolism and bacterial decomposition in the
gut lead to conversion of tyrosine to p-hydroxyphenylacetate,
the clearance of which by the normal human kidney equals or
may exceed the GFR [38, 39]. From reported urinary concen-
trations, we estimate the average daily excretion to be approx-
imately 20mg 139, 401. If the average plasma levels of 1.2 rg/ml
in uremic humans is correct [37], this compound with a specific
activity of 21 lnh.U./mg would account for only a minor
fraction of the binding inhibition in serum of patients with
advanced uremia. A more significant role for p-hydroxyphen-
ylacetate in uremia may be the inhibition of platelet aggregation
[41].
Likewise, the extent to which hippurate, indoxyl sulfate and
rn-HPHA account for the impaired ligand binding in uremic
serum depends on the levels they reach in uremic plasma and
their intrinsic potencies. Because hippurate and indoxyl sulfate
are secreted by the normal kidney and m-HPHA very likely is
secreted as well, it is reasonable to consider them as potential
uremic binding inhibitors. Substantial elevations of the plasma
concentrations of these compounds among patients with renal
failure have been reported, but the specificity of the methods
used is unknown [31—33, 42, 43]. We are in the process of
measuring the concentrations of these aromatic acids in uremic
plasma and correlating their concentrations with the inhibition
of binding by albumin of model probes. Our preliminary results
suggest that none of these acids alone account for more than a
modest portion of the total binding inhibition found in uremic
plasma [44]. Whether the acids acting in aggregate will account
for much of the inhibitory effect remains to be determined.
In the present study we used phenytoin as the test ligand to
search for binding inhibitors. Phenytoin has been used exten-
sively as a probe with both normal and uremic serum for one of
the two major drug binding loci of serum albumin, the
warfarin—azapropazone site [6]. This site also hinds furosemide,
diflunisal, salicylate and some sulfonamides and is a secondary
site for fatty acid binding. In future studies we will use
salicylate as the test ligand, because it hinds to both the
warfarin and indole sites of albumin [45].
Calculations by Roman et al showed that only about
one—third of the total binding inhibitory effect contained in
uremic plasma is recovered in our XAD-2 methanol wash [45].
A portion of the lost activity may be indoxyl sulfate (Table 2).
This very strong acid is fully ionized at pH 3 and, therefore, is
very weakly bound by the hydrophobic resin. Other methods
such as adsorption with an anion exchange resin or gel at
neutral pH, will have to be evaluated to determine whether
other binding inhibitors, like indoxyl sulfate, adsorb very
weakly to the XAD-2 resin.
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